Merck & Co., Inc. is a global healthcare company that develops and manufactures pharmaceuticals, vaccines, biologics, and animal health products. Its core products include treatments for cancer, diabetes, and infectious diseases, with significant revenue generated from its oncology and vaccine segments. The company also focuses on research and development to innovate new therapies and improve existing ones.
The stock presents a balanced investment profile, appealing to investors seeking a combination of growth and income through dividends. With a moderate dividend yield and a focus on innovation, it may attract those interested in stable returns while also considering potential capital appreciation.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-06-09 02:45 | Hold | Buy | Stable dividend, moderate growth, cautious market sentiment. |
| 2026-06-01 02:45 | Buy | Hold | Solid dividend yield, but mixed momentum signals. |
| 2026-05-24 02:45 | Hold | Buy | Strong momentum and solid dividend yield support growth. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-06-02 10:48 | Guggenheim | Update | — → 140 | 115.21 |
| 2026-05-01 16:03 | Morgan Stanley | Target Raised | 109 → 112 | 112.47 |
| 2026-03-12 11:05 | Wells Fargo | Target Raised | — → 150 | 116.22 |
